1. | catalystcrusin | |
2. | 48ncrebs | |
3. | blueauger497 | |
4. | 2017rogerthat |
1. | catalystcrusin | |
2. | 48ncrebs | |
3. | blueauger497 | |
4. | 2017rogerthat |
1. | 48ncrebs 10/07/2017 Downgrade in future? |
2. | 2017rogerthat 07/25/2018 Sees FY18 revs of $2.9-3.0 bln vs. $2.79 bln |
3. | 48ncrebs 07/10/2018 These Top stocks Are In Or Near Buy Range Amid New Stock Market Strength |
4. | blueauger497 02/01/2018 needs news - Barclays |
5. | 48ncrebs 06/18/2018 Announces that IRKAMBI to treat the underlying cause of cystic fibrosis (CF) |
6. | catalystcrusin 01/31/2018 Maxim Group reiterates Buy rating, $195 PT |
7. | catalystcrusin 01/23/2018 Breakout day #2 |
8. | catalystcrusin 02/12/2018 NEWS sounds good - Announces FDA approval of FDA SYMDEKO |
9. | catalystcrusin 10/07/2017 Dont really care what they say, for the more part they only care about themselves. |
10. | catalystcrusin 02/05/2018 Beats EPS estimates by $0.07 and beats on revenues |